-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia - What Clinicians Want to Know

Sponsor: an educational grant from Novartis
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
CML, Education, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Friday, December 6, 2024: 7:00 AM-10:00 AM
Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
Chair:
Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Mauro: Sun Pharma/SPARC: Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding.
Speakers:
Andreas Hochhaus, MD, Klinik für Innere Medizin II and Douglas Smith, Sidney Kimmel Comprehensive Cancer Center
Disclosures:
Hochhaus: Novartis: Honoraria, Other: Advisory Board, Research Funding; Enliven: Honoraria, Other: Advisory Board; Terns: Honoraria, Other: Advisory Board.

This 1.5-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with Chronic Myeloid Leukemia (CML). Three clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of CML. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.